<code id='C696ACE01D'></code><style id='C696ACE01D'></style>
    • <acronym id='C696ACE01D'></acronym>
      <center id='C696ACE01D'><center id='C696ACE01D'><tfoot id='C696ACE01D'></tfoot></center><abbr id='C696ACE01D'><dir id='C696ACE01D'><tfoot id='C696ACE01D'></tfoot><noframes id='C696ACE01D'>

    • <optgroup id='C696ACE01D'><strike id='C696ACE01D'><sup id='C696ACE01D'></sup></strike><code id='C696ACE01D'></code></optgroup>
        1. <b id='C696ACE01D'><label id='C696ACE01D'><select id='C696ACE01D'><dt id='C696ACE01D'><span id='C696ACE01D'></span></dt></select></label></b><u id='C696ACE01D'></u>
          <i id='C696ACE01D'><strike id='C696ACE01D'><tt id='C696ACE01D'><pre id='C696ACE01D'></pre></tt></strike></i>

          fashion

          fashion

          author:knowledge    Page View:1924
          Tome cofounders Jonathan Gootenberg, left, and Omar Abudayyeh, a scientific team that's trying to reinvent gene editing for a new era of biotech innovation.
          Suzanne Kreiter/Globe staff

          WATERTOWN — Their brainstorming began in an MIT class in 2010 when the eager undergrads shot each other emails about how to solve a bioengineering equation. It has continued for 14 years over sushi dinners, between Marvel movies, and during rowing-machine workouts.

          Together, Omar Abudayyeh, 33, and Jonathan Gootenberg, 32, have probed the mysteries of genomic editing and COVID detection. They co-published 10 scientific papers, helped launch two medical-diagnostic companies, and cofounded a Watertown startup, Tome Biosciences, that reengineers genes and cells to cure diseases. They also run the Abudayyeh-Gootenberg Lab at Harvard.

          advertisement

          Gootenberg and Abudayyeh are an unusual pair, two scientists — a Jewish American and a Palestinian American — who prefer working together in a field that often draws solitary researchers and rewards individual achievement.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more
          CDC picks Alphabet's Verily for wasterwater surveillance contract
          CDC picks Alphabet's Verily for wasterwater surveillance contract

          AdobeAlphabet’slifesciencescompanyVerilyhasscoreditsfirstCentersforDiseaseControlandPreventioncontra

          read more
          United colonoscopy coverage change 'may cost lives,' doctors say
          United colonoscopy coverage change 'may cost lives,' doctors say

          AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

          read more

          Fight over Supreme Court dialysis ruling puts kidney patients at risk

          AdobeAssoonassheheardtheSupremeCourtdecision,LaVarneBurtonbegantoworry.AsCEOofthenonprofitAmericanKi